Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Tax Provisions (2016 - 2025)

Cytosorbents (CTSO) has disclosed Tax Provisions for 12 consecutive years, with -$1.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Tax Provisions fell 107.78% year-over-year to -$1.7 million, compared with a TTM value of -$3.6 million through Mar 2025, changed N/A, and an annual FY2024 reading of -$1.7 million, down 107.78% over the prior year.
  • Tax Provisions was -$1.7 million for Q4 2024 at Cytosorbents, down from -$813739.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at -$736003.0 in Q4 2021 and bottomed at -$1.7 million in Q4 2024.
  • Average Tax Provisions over 5 years is -$1.1 million, with a median of -$1.1 million recorded in 2022.
  • The sharpest move saw Tax Provisions skyrocketed 34.7% in 2021, then plummeted 107.78% in 2024.
  • Year by year, Tax Provisions stood at -$1.1 million in 2020, then surged by 34.7% to -$736003.0 in 2021, then plummeted by 48.45% to -$1.1 million in 2022, then increased by 25.52% to -$813739.0 in 2023, then tumbled by 107.78% to -$1.7 million in 2024.
  • Business Quant data shows Tax Provisions for CTSO at -$1.7 million in Q4 2024, -$813739.0 in Q4 2023, and -$1.1 million in Q4 2022.